Demetrius Matassov

发表

Measurement of apoptosis by DNA fragmentation.

M. Sikorska, Z. Zakeri, J. Leblanc, 2004, Methods in molecular biology.

Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death

H. Feldmann, C. Happi, J. Eldridge, 2019, The Journal of clinical investigation.

Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

J. Eldridge, C. Mire, D. Clarke, 2015, Nature.

Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems.

D. Levy, A. García-Sastre, T. Muster, 1998, Virology.

A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).

A. Cupo, J. Galarza, D. Matassov, 2007, Viral immunology.

An introduction to the Marburg virus vaccine consortium, MARVAC

J. Dye, I. Longini, S. Günther, 2022, PLoS pathogens.

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge

J. Eldridge, M. Egan, T. Geisbert, 2022, bioRxiv.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus

H. Feldmann, A. Marzi, J. Eldridge, 2015, The Journal of infectious diseases.

Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.

J. Eldridge, Susan E. Witko, D. Clarke, 2020, The Lancet. Infectious diseases.

Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge

T. Rudge, C. Sabourin, J. Eldridge, 2017, Journal of Virology.

Immune correlates of postexposure vaccine protection against Marburg virus

J. Eldridge, C. Mire, I. Messaoudi, 2020, Scientific Reports.

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

J. Eldridge, C. Mire, T. Geisbert, 2018, The Journal of infectious diseases.

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.

A. Dimitrov, J. Eldridge, M. Egan, 2021, Vaccine.

mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.

A. García-Sastre, R. Lockshin, W. Malorni, 2014, Virology.

Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge

R. Tesh, S. Weaver, R. Gorchakov, 2017, Journal of Virology.

Lack of Bax Prevents Influenza A Virus-Induced Apoptosis and Causes Diminished Viral Replication

E. Datan, J. McLean, Z. Zakeri, 2009, Journal of Virology.